Archives: Agenda

Navigating the Evolving Biosimilars Landscape: Application of new FDA and EMA Guidance as illustrated with a biosimilar case study and implications for CROs

  • Learning from real-world case studies to accelerate biosimilar development and approval.
  • Understanding the EMA’s reflection paper and its role in shaping regulatory expectations.
  • Examining how a rapidly changing regulatory environment impacts development strategies.
  • Assessing the implications for CROs in supporting sponsors through this transition.

Built for Biotech: A Fit for Purpose FSP Model That Scales with Innovation

  • Designed for biotech: A Fit‑for‑Purpose FSP model, built with agility, to tailor to unique biotech needs
  • Scales with innovation: Flexible resourcing that grows with evolving pipelines, addressing clinical trial complexities in an ever-changing clinical trial and geopolitical landscape
  • Integrated expertise: Dedicated teams embedded as an extension of the sponsor with laser-focus on developing assets to time and quality
  • Enabling progress: Supporting development from early stages through commercialization